Eluvia drug-eluting vascular stent system for the treatment of symptomatic femoropopliteal lesions. (10th April 2018)

• Record Type: Journal Article
• Authors: Müller-Hülsbeck, Stefan; Hopf-Jensen, Silke; Keirse, Koen; Zeller, Thomas; Schroë, Herman; Diaz-Cartelle, Juan; Gray, William A
• Is Part Of: Future cardiology. Volume 14:Number 3(2018)
• Page Start: 207
• Page End: 213
• Publication Date: 2018-04-10
• Subjects: drug-eluting stent -- paclitaxel -- peripheral artery disease -- popliteal artery -- superficial femoral artery; Cardiology -- Research -- Periodicals; 616.12005
• DOI: 10.2217/fca-2017-0105
• Languages: English
• ISSNs: 1479-6678

Abstract

Endovascular options are increasingly recognized as primary treatments for lower extremity peripheral arterial disease inadequately responsive to noninvasive therapy. Options include balloon angioplasty and stent implantation, and newer technologies incorporate drug coatings to prevent restenosis and reduce the need for reintervention. The Eluvia drug-eluting vascular stent system (Boston Scientific, MA, USA) was designed with a biocompatible fluoropolymer coating to allow for drug elution over time. Initial clinical results demonstrate promising efficacy in terms of sustained femoropopliteal artery patency along with a good safety profile. This review summarizes the existing clinical literature on treatment of femoropopliteal artery lesions with Eluvia, and outlines the continuing research program.